CervoMed Inc. (CRVO)

In September 2025, CervoMed participated in investor conferences and highlighted neflamapimod's potential benefits for DLB at the American Neurological Association conference. In October 2025, the Chief Commercial and Business Officer presented at the Emerging Growth Conference, and company management participated in a panel discussion and meetings at the ROTH Healthcare Opportunities Conference. Additional data from the Phase 2b RewinD-LB trial of neflamapimod for DLB was shared, and the FDA provided feedback aligning on key elements of the planned global Phase 3 trial of neflamapimod for DLB, expected to start in the second half of 2026.

The provided information does not contain specific details regarding the demand seasonality for CervoMed Inc.'s products and services. Demand for neflamapimod is likely driven by disease prevalence and clinical trial success rather than typical seasonal patterns.

CervoMed Inc. is a clinical-stage biotechnology company focused on developing treatments for age-related neurologic disorders, operating within the Healthcare sector, specifically in the Biotechnology and Pharmaceutical Preparations industries. Their lead product candidate is neflamapimod, an orally administered small molecule brain penetrant that inhibits p38 alpha, a key driver of synaptic dysfunction. Neflamapimod is being evaluated in a Phase 2b study for patients with DLB, and the company has aligned with the FDA on the registration path for a planned global Phase 3 trial in DLB, expected to start in the second half of 2026. CervoMed is also developing EIP200 for the central nervous system, which is in preclinical trials.

CervoMed Inc. is headquartered in Boston, Massachusetts, United States. The company is planning a global Phase 3 trial for neflamapimod.

CervoMed Inc. is recognized for its scientific acumen, ethical practices, and patient-centric approach within the biopharmaceutical industry. The company has established a strong position in the MedTech and HealthAI sectors by focusing on precision diagnostics and AI-driven clinical workflow optimization. Their offerings are distinguished by an integrated suite of AI products for a holistic approach to diagnostics.

Insiders hold 35.40% of CervoMed's stock, with more stock purchased than sold in the past three months, totaling $737,723.00 in purchases and no sales. Institutions hold 25.15% of the stock.